Autoimmune therapy - Sanofi/Schrodinger
Latest Information Update: 28 May 2022
At a glance
- Originator Sanofi; Schrodinger
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 May 2022 No recent reports of development identified for clinical-Phase-Unknown development in Autoimmune-disorders in France
- 28 May 2022 No recent reports of development identified for clinical-Phase-Unknown development in Autoimmune-disorders in USA
- 09 Apr 2019 Clinical trials in Autoimmune disorders in France and USA (unspecified route)